The IMF CCO CME Friday Satellite Symposia is a physician educational activity that is available for those who register, either for the online virtual or in-person option.
The diagnosis of active multiple myeloma (MM) and when to initiate therapy for patients with MM continues to evolve as we learn more about the biology of this disease and how we can use various biomarkers to determine the risk of progression to active disease.
Currently, some consider beginning therapy for patients with smoldering multiple myeloma (SMM) once they have >50% risk of progression to active disease based on the 20/2/20 model. Some healthcare professionals feel uncomfortable and do not wish to start treatment for high-risk smoldering multiple myeloma (HRSMM), and ongoing monitoring happens. Today, we are hearing that we need more than the 20/2/20 model to determine treatment for HRSMM.
I’m sure some of the other #IMFASH21 Team Leaders will blog on other cases presented at the Symposium, but I’ll focus here on the HRSMM. Below is the excellent agenda for the IMF Symposium where 6 cases were presented, voted on, discussion ensued, voted on again.
Dr. Jesus San-Miguel (Clínica Universidad de Navarra – Pamplona, Spain) presented virtually on “Case Study 1: Evidence for Treating HRSMM.”
To Treat or Not to Treat for HRSMM:
When I was diagnosed 21 years ago, there was not even a classification of HRSMM vs SMM. I remember at previous ASH when these discussions and research first started and the interest that developed. Today we have from the International Myeloma Working Group (IMWG) progression risk by group, see below:
“Having these tools helps a SMM determine to treat or not to treat – but you need more than 2/20/20!” – Dr. Jesus San-Miguel.
Today, my rock n’ roll reference song is “Treat Me Right” by Pat Benatar (1980).
Enjoy!
Michael Tuohy, on Twitter: @IMFmikeMYELOMA
You must be logged in to post a comment.